Jane Street Group LLC Sells 6,945 Shares of ProKidney Corp. (NASDAQ:PROK)

Jane Street Group LLC lowered its stake in ProKidney Corp. (NASDAQ:PROK) by 14.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 40,530 shares of the company’s stock after selling 6,945 shares during the quarter. Jane Street Group LLC’s holdings in ProKidney were worth $78,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in PROK. AQR Capital Management LLC bought a new stake in ProKidney in the second quarter valued at about $50,000. Intech Investment Management LLC acquired a new position in shares of ProKidney during the 3rd quarter worth about $46,000. The Manufacturers Life Insurance Company acquired a new position in shares of ProKidney during the 2nd quarter worth about $60,000. Castleview Partners LLC acquired a new stake in shares of ProKidney in the 3rd quarter valued at approximately $63,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in ProKidney during the 2nd quarter worth approximately $106,000. Institutional investors and hedge funds own 51.59% of the company’s stock.

ProKidney Stock Performance

PROK stock opened at $1.58 on Thursday. The business’s 50-day moving average price is $1.82 and its two-hundred day moving average price is $2.01. ProKidney Corp. has a 1-year low of $1.18 and a 1-year high of $4.44. The firm has a market cap of $460.83 million, a PE ratio of -2.87 and a beta of 1.32.

ProKidney (NASDAQ:PROK) last announced its earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.14). On average, analysts forecast that ProKidney Corp. will post -0.57 earnings per share for the current year.

Analysts Set New Price Targets

Separately, JPMorgan Chase & Co. began coverage on shares of ProKidney in a research note on Monday, September 30th. They issued a “neutral” rating for the company. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, ProKidney presently has an average rating of “Hold” and an average price target of $4.50.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.